Amneal reaffirms FY2023 guidance: revenue $2.37-2.42B, adj. EBITDA $540-550M

Amneal Pharmaceuticals, Inc.

Reaffirmed 2023 guidance previously issued on Nov 7, 2023 at an investor conference on Jan 10, 2024.
Net revenue range $2.37-$2.42 billion; adjusted EBITDA $540-$550 million.
Adjusted diluted EPS $0.51-$0.58; operating cash flow $250-$280 million.
Capital expenditures $50-$60 million; weighted average diluted shares ~310 million.
Guidance includes 100% of AvKARE Adjusted EBITDA and 35% non-controlling interest in EPS.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Amneal Pharmaceuticals, Inc. reported year ended December 31, 2023 results: revenue $2.37 billion - $2.42 billion, EPS $0.51 - $0.58. Guidance reaffirmed.

Period: year ended December 31, 2023
Revenue: $2.37 billion - $2.42 billion
EPS: $0.51 - $0.58
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Amneal Pharmaceuticals, Inc., a Delaware corporation (the "Company"), reaffirmed guidance with respect to the year ended December 31, 2023, which was previously announced on November 7, 2023 in connection with announcing the Company's third quarter 2023 results: Net revenue $2.37 billion - $2.42 billion Adjusted EBITDA (1) $540 million - $550 million Adjusted diluted EPS (2) $0.51 - $0.58 Operating cash flow (3) $250 million - $280 million Capital expenditures $50 million - $60 million Weighted average diluted shares outstanding (4) Approximately 310 million

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Amneal Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001723128-24-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.